AC
ROIV icon

Aaron Cowen’s Roivant Sciences ROIV Stock Holding History

Aaron Cowen’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-681,528
Closed -$2.77M – 87
2022
Q2 		$2.77M Hold
681,528
– – 0.11% 75
2022
Q1 		$3.37M Hold
681,528
– – 0.1% 68
2021
Q4 		$6.87M Buy
+681,528
New +$5.67M 0.13% 69

Other funds holding ROIV

QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.2B AUM 23.01% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Aaron Cowen's ROIV Position: Q3 2022 in Review

Aaron Cowen sold out of Roivant Sciences (ROIV) in Q3 2022, closing a stake of 681,528 shares — an estimated $2.77M sold.

Aaron Cowen first reported a position in ROIV in Q4 2021 and held it in 3 quarters. The position peaked at $6.87M in Q4 2021. 78 funds tracked by Wall St. Rank hold ROIV as of Q3 2022.

  • Aaron Cowen reported no remaining Roivant Sciences position as of Q3 2022 after selling out during the quarter.
  • Aaron Cowen sold 681,528 Roivant Sciences shares in Q3 2022, an estimated $2.77M.
  • Aaron Cowen first reported a position in Roivant Sciences in Q4 2021 and held it in 3 quarters.
  • Aaron Cowen's Roivant Sciences position peaked at $6.87M in Q4 2021.
  • 78 funds tracked by Wall St. Rank held Roivant Sciences as of Q3 2022.

Based on Suvretta Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.